Clearmind Medicine logo

Clearmind MedicineNASDAQ: CMND

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

15 November 2022

Next earnings report:

31 December 2024

Last dividends:

N/A

Next dividends:

N/A
$5.88 M
-59%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
52%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 69 min ago
$1.45-$0.00(-0.04%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CMND Latest News

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
globenewswire.com10 October 2024 Sentiment: POSITIVE

FDA approval for the IND submission to conduct its trial already secured Vancouver, Canada, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has received Institutional Review Board (IRB) approval from one of its clinical sites in the U.S. for part A of its Phase I/IIa clinical trial in the United States for treating patients suffering from alcohol use disorder (AUD). The multinational, multi-center trial will assess the safety, tolerability, and pharmacokinetics of Clearmind's innovative MEAI-based (5-methoxy-2-aminoindane) treatment, CMND-100.

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
globenewswire.com16 September 2024 Sentiment: POSITIVE

Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
globenewswire.com12 September 2024 Sentiment: POSITIVE

Innovative compounds designed to address critical unmet needs in PTSD treatment Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the International Patent Cooperation Treaty (“PCT”).

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
globenewswire.com06 September 2024 Sentiment: POSITIVE

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
globenewswire.com29 August 2024 Sentiment: POSITIVE

Vancouver, Canada, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced the publication of its patent application under the international Patent Cooperation Treaty (“PCT”) for innovative combinations of Ketamine and N-Acylethanolamines.

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
globenewswire.com21 August 2024 Sentiment: POSITIVE

Vancouver, Canada, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received a new patent approval from the United States Patent and Trademark Office, marking another significant advancement in its proprietary MEAI-based binge behavior regulator program.

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
globenewswire.com16 August 2024 Sentiment: POSITIVE

Vancouver, Canada, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the international Patent Cooperation Treaty (“PCT”) as part of the company's ongoing collaboration with the with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”) pursuant to the exclusive licensing agreement that the Company entered into with Yissum.

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
globenewswire.com19 July 2024 Sentiment: POSITIVE

Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced a strategic engagement with JS First Sdn. Bhd (“JS First”). This partnership aims to source global manufacturers and distributors for Clearmind's groundbreaking MEAI-based alcohol substitute beverages, marking a significant step towards international expansion.

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
globenewswire.com16 July 2024 Sentiment: POSITIVE

Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that  the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule, allowing the Company to proceed with a Phase I/IIa clinical trial in the United States for treating patients with alcohol use disorder (AUD). While the Phase I/IIa clinical trial was already approved in Israel, clearance from the FDA will allow the trial to be initiated in the US.

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
globenewswire.com16 July 2024 Sentiment: POSITIVE

Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted an additional patent application with the United States Patent and Trademark Office (“USPTO”), as part of its ongoing collaborations with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with invented with Prof. Joseph Tam from the Hebrew University's technology transfer company, Yissum.

  • 1(current)

What type of business is Clearmind Medicine?

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

What sector is Clearmind Medicine in?

Clearmind Medicine is in the Healthcare sector

What industry is Clearmind Medicine in?

Clearmind Medicine is in the Biotechnology industry

What country is Clearmind Medicine from?

Clearmind Medicine is headquartered in Canada

When did Clearmind Medicine go public?

Clearmind Medicine initial public offering (IPO) was on 15 November 2022

What is Clearmind Medicine website?

https://www.clearmindmedicine.com

Is Clearmind Medicine in the S&P 500?

No, Clearmind Medicine is not included in the S&P 500 index

Is Clearmind Medicine in the NASDAQ 100?

No, Clearmind Medicine is not included in the NASDAQ 100 index

Is Clearmind Medicine in the Dow Jones?

No, Clearmind Medicine is not included in the Dow Jones index

When was Clearmind Medicine the previous earnings report?

No data

When does Clearmind Medicine earnings report?

The next expected earnings date for Clearmind Medicine is 31 December 2024